Open access · CC-BY
via OpenAlex
Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins
Katherine H. Schreiber, Denise Ortiz, Emmeline C. Academia, Arieanna C. Anies, Chen‐Yu Liao, Brian Keith Kennedy
Aging Cell · 2015 · ▲ 178 citations
Abstract
The mechanism by which the drug mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) inhibits the mechanistic target of rapamycin (mTOR) is of intense interest because of its likely relevance in cancer biology, aging, and other age-related diseases. While rapamycin acutely and directly inhibits mTORC1, only chronic administration of rapamycin can inhibit mTORC2 in some, but not all, cell lines or tissues. The mechanism leading to cell specificity of mTORC2 inhibition by rapamycin is not understood and is especially important because many of the negative metabolic side effects of rapamycin, reported in mouse studies and human clinical trials, have been attributed recently to mTORC2 inhibition. Here, we identify the expression level of different FK506-binding proteins (FKBPs), primarily FKBP12 and FKBP51, as the key determinants for rapamycin-mediated inhibition of mTORC2. In support, enforced reduction of FKBP12 completely converts a cell line that is sensitive to mTORC2 inhibition to an insensitive cell line, and increased expression can enhance mTORC2 inhibition. Further reduction of FKBP12 in cell lines with already low FKBP12 levels completely blocks mTORC1 inhibition by rapamycin, indicating that relative FKBP12 levels are critical for both mTORC1 and mTORC2 inhibition, but at different levels. In contrast, reduction of FKBP51 renders cells more sensitive to mTORC2 inhibition. Our findings reveal that the expression of FKBP12 and FKBP51 is the rate limiting factor that determines the responsiveness of a cell line or tissue to rapamycin. These findings have implications for treating specific diseases, including neurodegeneration and cancer, as well as targeting aging in general.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/acel.12313
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Schreiber, K.H., Ortiz, D., Academia, E.C., Anies, A.C., Liao, C., & Kennedy, B.K. (2015). Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins. <em>Aging Cell</em>. https://doi.org/10.1111/acel.12313
Vancouver
Schreiber KH, Ortiz D, Academia EC, Anies AC, Liao C, Kennedy BK. Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins. Aging Cell. 2015. doi:10.1111/acel.12313.
BibTeX
@article{katherine2015Rapamy,
title = {Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins},
author = {Katherine H. Schreiber and Denise Ortiz and Emmeline C. Academia and Arieanna C. Anies and Chen‐Yu Liao and Brian Keith Kennedy},
journal = {Aging Cell},
year = {2015},
doi = {10.1111/acel.12313},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The FASEB Journal 2013
Citation only
Natural killer cell maturation is blocked by mTOR inhibition in C57Bl/6 mice
Cancer Biology & Therapy 2014
Open access · OA
mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels
Journal of Biological Chemistry 2013
Open access · CC-BY
A Novel Sirtuin 2 (SIRT2) Inhibitor with p53-dependent Pro-apoptotic Activity in Non-small Cell Lung Cancer
Research and Reports in Biology 2015
Open access · CC-BY
Recent insights into the pathophysiology of mTOR pathway dysregulation
bioRxiv (Cold Spring Harbor Laboratory) 2023
Preprint · OA
Living cell mTORC1 inhibition reporter mTIR reveals nutrient-sensing targets of histone deacetylase inhibitor
EXCLI journal 2019
Open access · CC-BY